| Cat.No. | Name | Information |
|---|---|---|
| M2411 | Picropodophyllin (AXL1717) | AXL1717 (picropodophyllin, Picropodophyllotoxin, PPP) is a non-competitive, potent, and specific inhibitor of IGF-1Rα/β with IC50 of 1 nM. |
| M2192 | BMS-754807 | Bms-754807 is a potent igf-1r /InsR reversible inhibitor with an IC50 of 1.8 nM/1.7 nM and also inhibits the activity of Met, RON, TrkA, TrkB, AurA and AurB with an IC50 value of 6,44,7,4, respectively. At 9 and 25 nM, it has almost no inhibitory activity against Flt3, Lck, MK2, PKA and PKC. |
| M2025 | PQ401 | PQ401 is an insulin growth factor-1 receptor (IGF-1R) inhibitor. PQ401 inhibits IGF-I-stimulated IGF-IR autophosphorylation with an IC50 of 12.0 μM in a series of studies in MCF-7 cells. PQ401 is effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 μM). |
| M45208 | GIP, human | GIP, human is a peptide hormone consisting of 42 amino acids that also acts as a promoter of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. In addition, GIP, human acts as an enteric proinsulin hormone released by intestinal K cells in response to nutrient intake. |
| M30009 | NBI-31772 | NBI-31772 is the potent and nonselective inhibitor of IGFBP with a Ki value of 47 nM. NBI-31772 has the potential for the research of IGF-responsive diseases. |
| M25306 | Cixutumumab | Cixutumumab (IMC-A12) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. |
| M25296 | Figitumumab | Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. |
| M25294 | Robatumumab | Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research. |
| M25276 | Ganitumab | Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer. |
| M24540 | Teprotumumab | Teprotumumab (RV001, R1507) is a first-in-class IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research. |
| M20615 | NT157 | NT157, a selective inhibitor of IRS-1/2(insulin receptor substrate), has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival. |
| M14903 | GIP, human TFA | GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. |
| M7685 | Chromeceptin | Chromeceptin inhibits Insulin-like growth factor 2 (IGF2) signaling by a process that begins with chromeceptin binding to multifunctional protein 2 (MFP-2). |
| M7067 | NVP ADW 742 | Nvp-adw742 (ADW742) is an orally active, selective igF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. Nvp-adw742 inhibited insulin receptor (InsR) with IC50 of 2.8 μM. Nvp-adw742 induces multipotent anti-proliferation/pro-apoptosis in tumor cells. |
| M4090 | Ginsenoside-Rg5 | Ginsenoside Rg5 is the main ingredient of red ginseng. Ginsenoside Rg5 blocks the binding of IGF-1 to its receptor with an IC50 of about 90 nM. Ginsenoside Rg5 also inhibited COX-2 mRNA expression by inhibiting DNA binding activity of NF-κB P65. |
| M3744 | NVP-AEW541 | NVP-AEW541 is a novel, potent and selective inhibitor of IGF-IR kinase with IC50 value of 0.086. |
| M3397 | AG-1024 | AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins). |
| M1957 | BMS-536924 | Bms-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50 of 100 nM and 73 nM, respectively. It also showed moderate inhibitory activity against Mek, Fak and Lck, but almost no inhibitory activity against Akt1 and MAPK1/2. |
| M1821 | OSI-906 | OSI-906 (Linsitinib) is a potent, selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with IC50 values of 35 nM and 75 nM respectively. |
| M1792 | XL228 | XL228 is a potent multikinase small-molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
